Amicus Therapeutics Inc FOLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FOLD is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $10.52
- Day Range
- $10.03–10.40
- 52-Week Range
- $9.70–14.57
- Bid/Ask
- $10.15 / $10.16
- Market Cap
- $3.00 Bil
- Volume/Avg
- 1.9 Mil / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 517
- Website
- https://www.amicusrx.com
Competitors
Valuation
|
Metric
|
FOLD
|
BMRN
|
|---|---|---|
Price/Earnings (Normalized) | — | 109.91 |
Price/Book Value | 19.33 | 3.40 |
Price/Sales | 7.79 | 7.11 |
Price/Cash Flow | — | 34.79 |
Price/Earnings
FOLD
BMRN
Financial Strength
|
Metric
|
FOLD
|
BMRN
|
|---|---|---|
Quick Ratio | 2.23 | 1.45 |
Current Ratio | 2.88 | 2.51 |
Interest Coverage | −2.13 | 8.78 |
Quick Ratio
FOLD
BMRN
Profitability
|
Metric
|
FOLD
|
BMRN
|
|---|---|---|
Return on Assets (Normalized) | −5.21% | 6.15% |
Return on Equity (Normalized) | −30.55% | 8.47% |
Return on Invested Capital (Normalized) | −0.78% | 6.27% |
Return on Assets
FOLD
BMRN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jydcyljmm | Fsznc | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gqpjzlw | Nslxqp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pljydfmn | Hxksklm | $99.5 Bil | |
MRNA
| Moderna Inc | Dgzbrhfq | Rfzb | $38.8 Bil | |
ARGX
| argenx SE ADR | Lpgpmkjj | Vdq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dcdwkwccc | Rbb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cghhbcf | Ctslpt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qzcxtdcl | Xwxmhqx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vzvhnplyy | Dchjz | $12.5 Bil | |
INCY
| Incyte Corp | Fbdjysk | Hqvxsh | $11.6 Bil |